Caspases (Cysteine dependant Aspartate Specific Proteases) form a family of closely related enzymes (family C14; clan CD) involved in regulating a type of cell death known as apoptosis, inflammatory responses, cellular proliferation and differentiation. Distinct caspases and caspase combinations are employed in these pathways dependent upon stimulus and cell type.

Caspases are synthesized as inactive precursors (zymogens). These procaspases consist of a prodomain, followed by a large subunit, a linker, and a small subunit. Maximally active caspases are dimeric and stabilized by cleavage between the large and small subunit. In the case of apoptotic "initiator" caspases (caspases 2/8/9/10), activation is thought to be triggered by dimerization of zymogen monomers, which is mediated by scaffold proteins. Auto-cleavage follows dimerization and stabilizes the active confirmation or procures further regulation properties. In contrast, "effector" caspases (caspases 3/6/7) exist as inactive dimers and cleavage of the inter-subunit linker by initiator caspases results in their activation. Four multiprotein complexes involved in the activation of initiator caspases have been described so far: the death inducing signaling complex (DISC, caspases 8/10), the apoptosome (caspase-9), the inflammasomes complexes (inflammatory caspases-1 and -5) and the PIDDosome (caspase-2).

Caspases exert their activity by cleaving a limited set of proteins, mostly at a single site. Cleavage by caspases can result in protein or enzyme activation, loss of function and/or generation of new activities. In this context, identification, characterization and elucidation of the physiological significance of cellular caspase substrates remains an intensely studied area.

Like other members of clan CD, the caspase catalytic dyad involves coordination of a histidine-cysteine pair. All caspases have a strict requirement for an aspartate residue in P1 position of the scissile bond and weaker preferences for P2-P4. Roughly, inflammatory caspases and caspase-14 prefer WEHD peptidic sequences (aromatic in P4). Caspases 2/3/7 prefer DEVD containing substrates (aspartate in P4). Caspases 6/8/10 prefer (V/I/L)ETD (hydrophobic residues in P4), whereas caspase-9 cleaves after LEHD motif (histidine in P2 is strongly preferred). Notably, all caspases share preference for glutamate in P3 and small residues (Ser/Gly/Ala) in P1' of the recognition sequence. Cleavage is not limited to these preferred motifs, as, for example, both caspases 8/9 can activate pro-caspase-7 by cleavage at a non-optimal site, IQAD↓S. The context within the structure of the substrate, cellular localization and timing might influence the ability of a given caspase to cleave a given protein as much as the substrate sequence itself.

Human IAPs (Inhibitors of APoptosis) were the first identified endogenous caspase inhibitors of which, the X-linked IAP (XIAP) is the best characterized so far. Sequences encompassing XIAP's Baculovirus Inhibitory Repeat domains (Bir2 and Bir3) inhibit caspases 3/7 and caspase-9 respectively. These XIAP derived domains are the most specific and potent caspase inhibitors known to date. Although other IAPs (cIAP1, cIAP2, NAIP, ML-IAP, ILP2, Bruce and Survivin) have been shown to inhibit caspases, their physiological roles may involve other functions. Regardless, these and other cellular regulators of caspases have been shown to be misregulated in cancer, thereby providing a survival advantage during the oncogenic process and facilitating resistance to therapies. Pathogens have evolved inhibitors of caspases as well. The cowpox viral serpin CrmA, for example, is a powerful inhibitor of caspases 1/8, allowing the virus to evade the host inflammatory response and block initiation of host cell apoptosis induced by immune cells.

Currently available synthetic caspase inhibitors are based on the peptidic sequences preferred as substrates and include an active warhead such as aldehyde, chloro- or fluro-methylketone or epoxide group. Specific non-peptidic inhibitors of caspases are nonexistent with the exception of isatin sufonamides derivatives demonstrated to bind selectively to caspases 3/7. Finally, like many proteases of the CD clan, caspases are not inhibited by E-64, but are sensitive to cysteine alkylating agents. Caspase inhibitors have served as valuable tools in the elucidation of apoptosis pathways and have been proposed as therapeutics in a variety of diseases where inappropriate or excessive apoptosis occurs. Small molecule caspase inhibitors are currently in clinical trials for treatment of liver diseases and transplantation.

Many agents have been reported to activate cellular caspases including chemotherapeutic drugs, TNF receptor agonists and other enzymes such as granzyme B. Aside from direct activation by other enzymes, caspase activation by small molecules, TNF ligands and antibody agonists is indirect with the complete elucidation of these pathways under investigation. Development of directly targeted drugs that result in caspase activation and apoptosis specifically in cancer cells is an ongoing strategy in oncology.

The section and Table below contain accepted modulators and additional information. For a list of additional products, see the Materials section below.


  • Cisplatin (P4394) - caspase 3 activator
  • Gambogic acid (G8171) - caspase activator and apoptosis inducer
  • Imiquimod (I5159) - caspase 3 activator
  • PAC-1 (P0115) - caspase 3 activator
  • SMAC/Diablo human (S5941) - promotes caspase activation


  • Ac-WEHD-CHO (A1466) - very potent caspase 1 and 5 inhibitor
  • Cell Permeable Caspase 4 Inhibitor (SCP0115) - caspase 4 inhibitor
  • Z-DEVD-FMK (C0605) - competitive, irreversible, cell-permeable inhibitor of caspase 3, 6, 7, 8, 10
  • Z-LEHD-FMK (C1355) - competitive, irreversible, cell-permeable inhibitor of caspase 9
  • Z-VAD-FMK (C2105, V116) - competitive, irreversible inhibitor of caspase 1, as well as other caspases
  • Z-VDVAD-FMK (C1605) - competitive, irreversible, cell-permeable inhibitor of caspase 2


  • Ac-LETD-AFC (SCP0096) - fluorogenic substrate for caspase-8


An earlier report suggested the existence of a human caspase-13 (ERICE, a novel FLICE-activatable caspase J. Biol. Chem., 273 ,15702-15707 (1998), but further analysis revealed that the original library was contaminated with bovine cDNAs. Mice also express caspase-12 that seems implicated in endoplasmic reticulum stress response. This protein is catalytically inactive because it lacks a critical residue (Arg341 in caspase-1 numbering system). In human a pseudogene exist but is expressed only in a subpopulation of African descents as an inactive protein. Saleh, M, et al., Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms., Nature, 429, 75-79 (2004).

a) The MEROPS ( database contains information about peptidases and the proteins that inhibit them. It is maintained by Neil D. Rawlings, Fraser R. Morton and Alan J. Barrett at the Wellcome Trust Sanger Institute, Cambs CB10 1SA, UK.

b) Many substrates carrying various fluorogenic and chromogenic groups are normally used. Those include Afc (7-amino-4-trifluoro methylcoumarin), Amc (7-amino-4-methyllcoumarin) and pNA (p-nitroanilide). In principle, inhibitors composed of the preferred substrate peptide moiety and an inhibitor warhead constitute the preferred inhibitor. Warhead may include but is not limited to aldehyde (CHO), fmk (fluromethylketone) and epoxides. Chloromethylketone are not recommended since General inhibitors (pan-caspase inhibitors) are Z-VAD-FMK and Z-EVD-FMK and to a lesser extend BAF (Z-D-FMK).


Bir: Baculovirus inhibitory repeat
CARD: Caspase recruitment domain
CHO: Aldehyde
CrmA: Cytokine responsive modifier A
DED: Death effector domain
DISC: Death inducing signaling complex
GrB: Granzyme B
IAP: Inhibitor of apoptosis protein
ICAD: Inhibitor of caspase-activated DNase
ILP2: IAP-like protein-2
ML-IAP: Melanoma IAP
MMPSI: (S)-(+)-5-[1-(2-Methoxymethylpyrrolidinyl)sulfonyl]isatin
PARP: Poly (ADP-ribose) polymerase
PIDD: P53 induced protein with a death domain
XIAP: X-linked inhibitor of apoptotic proteases



Adams JM, Cory S. 2002. Apoptosomes: engines for caspase activation. Current Opinion in Cell Biology. 14(6):715-720.
Chen J, Rawlings ND, Stevens RA, Barrett AJ. 1998. Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases. 441(3):361-365.
Cheng G, Kong R, Zhang L, Zhang J. 2012. Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies. 167(4):699-719.
Dill KA, MacCallum JL. 2012. The Protein-Folding Problem, 50 Years On. Science. 338(6110):1042-1046.
Fischer U, Jänicke RU, Schulze-Osthoff K. 2003. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ. 10(1):76-100.
FUENTES-PRIOR P, SALVESEN G. 2004. The protein structures that shape caspase activity, specificity, activation and inhibition. 384(2):201-232.
Hyman BT, Yuan J. 2012. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat Rev Neurosci. 13(6):395-406.
James KE, Asgian JL, Li ZZ, Ekici ÖD, Rubin JR, Mikolajczyk J, Salvesen GS, Powers JC. 2004. Design, Synthesis, and Evaluation of Aza-Peptide Epoxides as Selective and Potent Inhibitors of Caspases-1, -3, -6, and -8. J. Med. Chem.. 47(6):1553-1574.
Ting J. 2002. Faculty Opinions recommendation of The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta..
Peter ME, Krammer PH. 2003. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10(1):26-35.
Pop C, Salvesen GS. 2009. Human Caspases: Activation, Specificity, and Regulation. J. Biol. Chem.. 284(33):21777-21781.
Powers JC, Asgian JL, Ekici ÖD, James KE. 2002. Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases. Chem. Rev.. 102(12):4639-4750.
Reed JC. 2002. Apoptosis-based therapies. Nat Rev Drug Discov. 1(2):111-121.
Salvesen GS, Duckett CS. 2002. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 3(6):401-410.
STENNICKE HR, RENATUS M, MELDAL M, SALVESEN GS. 2000. Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8. 350(2):563-568.
Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, et al. 1997. A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B. J. Biol. Chem.. 272(29):17907-17911.

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.